About Silvergate Pharma
Silvergate Pharma is a company based in Greenwood Village (United States) founded in 2010 was acquired by Azurity Pharmaceuticals in June 2019. Silvergate Pharma has raised $30.75 million across 4 funding rounds from investors including Frazier Healthcare Partners and Azurity Pharmaceuticals. Silvergate Pharma operates in a competitive market with competitors including Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Tenaya Therapeutics, among others.
- Headquarter Greenwood Village, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$30.75 M (USD)
in 4 rounds
-
Latest Funding Round
$4.6 M (USD), Series B
Oct 03, 2016
-
Investors
Frazier Healthcare Partners
& 1 more
-
Employee Count
Not available
-
Acquired by
Azurity Pharmaceuticals
(Jun 12, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Silvergate Pharma
Unlock access to complete
Unlock access to complete
Software Development Team
39 people
Leadership Team
29 people
Sales and Marketing
13 people
Product Management Team
8 people
Senior Team
8 people
Data Analysis and Operations Team
8 people
Operations Team
5 people
Human Resources and Administration
4 people
Unlock access to complete
Funding Insights of Silvergate Pharma
Silvergate Pharma has successfully raised a total of $30.75M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $4.6 million completed in October 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Silvergate Pharma
Silvergate Pharma has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Frazier Healthcare Partners and Azurity Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare sector private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
Generic drugs are manufactured by Azurity Pharmaceuticals in the US.
|
Locked | Locked | Locked |
Investor details for Silvergate Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Silvergate Pharma
Investment portfolio details for Silvergate Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Silvergate Pharma
Detailed financials for Silvergate Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Silvergate Pharma Comparisons
Peer comparison for Silvergate Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Silvergate Pharma
Silvergate Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Tenaya Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for cardiovascular and autoimmune diseases are developed.
|
|
| Locked | Locked | Locked |
Specialized drugs are developed for genetic heart diseases.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Provider of tools for the analysis of RNA structures
|
|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| Locked | Locked | Locked |
Innovative pharmaceuticals for cardiovascular and metabolic diseases are developed.
|
Detailed competitors of Silvergate Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Silvergate Pharma
Complete news archive for Silvergate Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Silvergate Pharma
Silvergate Pharma was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Silvergate Pharma is headquartered in Greenwood Village, United States. It is registered at Greenwood Village, Colorado, United States.
Frank Segrave is the current CEO of Silvergate Pharma.
Silvergate Pharma is a funded company, having raised a total of $30.75M across 4 funding rounds to date.
Silvergate Pharmaceuticals was founded in 2010 and is based in Greenwood Village, United States. Operations focus on the pharmaceutical sector, with manufacturing centered on products for pediatric patients. A single product, Epaned, is currently available for treating high blood pressure in adults and children over one month old, symptomatic heart failure, and asymptomatic left ventricular dysfunction to reduce overt heart failure development and hospitalizations.
Silvergate Pharma's top competitors include Tenaya Therapeutics, Cellino and MyoKardia.
Silvergate Pharma has 2 investors. Key investors include Frazier Healthcare Partners, and Azurity Pharmaceuticals.